MA53909A - Compositions et méthodes de stimulation ovarienne contrôlée - Google Patents
Compositions et méthodes de stimulation ovarienne contrôléeInfo
- Publication number
- MA53909A MA53909A MA053909A MA53909A MA53909A MA 53909 A MA53909 A MA 53909A MA 053909 A MA053909 A MA 053909A MA 53909 A MA53909 A MA 53909A MA 53909 A MA53909 A MA 53909A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- methods
- ovarian stimulation
- controlled ovarian
- controlled
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746812P | 2018-10-17 | 2018-10-17 | |
| EP18203167 | 2018-10-29 | ||
| EP19794444.0A EP3866833B1 (fr) | 2018-10-17 | 2019-10-17 | Compositions comprenant de la fsh recombinante pour le traitement de l'infertilité |
| PCT/EP2019/078170 WO2020079127A1 (fr) | 2018-10-17 | 2019-10-17 | Compositions et méthodes de stimulation ovarienne contrôlée |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA53909A true MA53909A (fr) | 2022-01-26 |
| MA53909B1 MA53909B1 (fr) | 2025-07-31 |
Family
ID=68344788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53909A MA53909B1 (fr) | 2018-10-17 | 2019-10-17 | Compositions et méthodes de stimulation ovarienne contrôlée |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US12311012B2 (fr) |
| EP (2) | EP4516354A3 (fr) |
| JP (2) | JP7555915B2 (fr) |
| KR (1) | KR20210079276A (fr) |
| CN (1) | CN112789053A (fr) |
| AU (1) | AU2019363279B2 (fr) |
| BR (1) | BR112021005019A2 (fr) |
| CA (1) | CA3110205A1 (fr) |
| CL (2) | CL2021000928A1 (fr) |
| CO (1) | CO2021005872A2 (fr) |
| DK (1) | DK3866833T3 (fr) |
| ES (1) | ES3026229T3 (fr) |
| FI (1) | FI3866833T3 (fr) |
| HR (1) | HRP20250463T1 (fr) |
| HU (1) | HUE070973T2 (fr) |
| IL (1) | IL280750B1 (fr) |
| JO (1) | JOP20210025B1 (fr) |
| LT (1) | LT3866833T (fr) |
| MA (1) | MA53909B1 (fr) |
| MD (1) | MD3866833T2 (fr) |
| MX (1) | MX428677B (fr) |
| MY (1) | MY210133A (fr) |
| PH (1) | PH12021550417A1 (fr) |
| PL (1) | PL3866833T3 (fr) |
| RS (1) | RS66713B1 (fr) |
| SG (1) | SG11202102340RA (fr) |
| SI (1) | SI3866833T1 (fr) |
| TW (1) | TWI846743B (fr) |
| UA (1) | UA128731C2 (fr) |
| WO (1) | WO2020079127A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3973982T1 (sl) | 2017-09-01 | 2024-10-30 | Ferring B. V. | Sestavek za nadzorovano stimulacijo jajčnikov |
| TW202237173A (zh) * | 2020-12-09 | 2022-10-01 | 荷蘭商菲林公司 | 用於受控的卵巢刺激之組成物及方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60238490D1 (de) * | 2001-09-12 | 2011-01-13 | Merck Serono Sa | Verwendung von humanem choriongonadotropin (hcg) und luteinisierendem hormon (lh) zur regulierten hyperstimulation der eierstöcke |
| EP1364658A1 (fr) * | 2002-05-24 | 2003-11-26 | Applied Research Systems ARS Holding N.V. | Utilisation de rapports variables de gonadotrophines dans l'hyperstimulation ovarienne contrôlée |
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| WO2012168680A1 (fr) | 2011-06-06 | 2012-12-13 | Ferring B.V. | Préparation pharmaceutique |
| JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
| WO2014125363A1 (fr) | 2013-02-15 | 2014-08-21 | Sung Kwang Medical Foundation | Production de cellules souches parthénogénétiques et de cellules souches embryonnaires humaines spécifiques d'un patient par transfert nucléaire de cellules somatiques |
| HUE054300T2 (hu) * | 2015-04-17 | 2021-08-30 | Ferring Bv | FSH-t tartalmazó, meddõség kezelésére szolgáló készítmény |
| SI3973982T1 (sl) | 2017-09-01 | 2024-10-30 | Ferring B. V. | Sestavek za nadzorovano stimulacijo jajčnikov |
| WO2019211153A1 (fr) | 2018-04-30 | 2019-11-07 | Ferring B.V. | Composition destinée à la stimulation ovarienne contrôlée |
| TW202237173A (zh) | 2020-12-09 | 2022-10-01 | 荷蘭商菲林公司 | 用於受控的卵巢刺激之組成物及方法 |
-
2019
- 2019-10-16 TW TW108137295A patent/TWI846743B/zh active
- 2019-10-17 DK DK19794444.0T patent/DK3866833T3/da active
- 2019-10-17 LT LTEPPCT/EP2019/078170T patent/LT3866833T/lt unknown
- 2019-10-17 SI SI201930926T patent/SI3866833T1/sl unknown
- 2019-10-17 AU AU2019363279A patent/AU2019363279B2/en active Active
- 2019-10-17 FI FIEP19794444.0T patent/FI3866833T3/fi active
- 2019-10-17 ES ES19794444T patent/ES3026229T3/es active Active
- 2019-10-17 JP JP2021521140A patent/JP7555915B2/ja active Active
- 2019-10-17 CA CA3110205A patent/CA3110205A1/fr active Pending
- 2019-10-17 MY MYPI2021002006A patent/MY210133A/en unknown
- 2019-10-17 RS RS20250371A patent/RS66713B1/sr unknown
- 2019-10-17 EP EP25150679.6A patent/EP4516354A3/fr active Pending
- 2019-10-17 PL PL19794444.0T patent/PL3866833T3/pl unknown
- 2019-10-17 HU HUE19794444A patent/HUE070973T2/hu unknown
- 2019-10-17 UA UAA202102528A patent/UA128731C2/uk unknown
- 2019-10-17 MX MX2021004383A patent/MX428677B/es unknown
- 2019-10-17 MD MDE20210789T patent/MD3866833T2/ro unknown
- 2019-10-17 MA MA53909A patent/MA53909B1/fr unknown
- 2019-10-17 HR HRP20250463TT patent/HRP20250463T1/hr unknown
- 2019-10-17 WO PCT/EP2019/078170 patent/WO2020079127A1/fr not_active Ceased
- 2019-10-17 IL IL280750A patent/IL280750B1/en unknown
- 2019-10-17 CN CN201980064065.3A patent/CN112789053A/zh active Pending
- 2019-10-17 BR BR112021005019-1A patent/BR112021005019A2/pt unknown
- 2019-10-17 SG SG11202102340RA patent/SG11202102340RA/en unknown
- 2019-10-17 EP EP19794444.0A patent/EP3866833B1/fr active Active
- 2019-10-17 US US17/285,314 patent/US12311012B2/en active Active
- 2019-10-17 KR KR1020217008853A patent/KR20210079276A/ko not_active Ceased
-
2021
- 2021-02-07 JO JOJO/P/2021/0025A patent/JOP20210025B1/ar active
- 2021-02-26 PH PH12021550417A patent/PH12021550417A1/en unknown
- 2021-04-15 CL CL2021000928A patent/CL2021000928A1/es unknown
- 2021-05-04 CO CONC2021/0005872A patent/CO2021005872A2/es unknown
-
2022
- 2022-03-29 CL CL2022000779A patent/CL2022000779A1/es unknown
-
2024
- 2024-06-24 JP JP2024100990A patent/JP2024133520A/ja active Pending
-
2025
- 2025-05-06 US US19/200,288 patent/US20250325637A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271025A (en) | Multibiotic agents and methods of using the same | |
| MA47611A (fr) | Compositionset méthodes de transduction tumorale | |
| EP3607072A4 (fr) | Compositions et méthodes de traitement de la phénylcétonurie | |
| MA46481A (fr) | Compositions d'oligonucléotides et méthodes associées | |
| IL283967A (en) | Modulators of hsd17b13 expression | |
| EP3595653A4 (fr) | Compositions de plinabuline et leur utilisation | |
| EP3328363A4 (fr) | Compositions et méthodes d'immunomodulation | |
| SI3743406T1 (sl) | Modulatorji TMEM16A | |
| MA46102A (fr) | Composés de tétracycline et méthodes de traitement | |
| EP3687981A4 (fr) | Compositions et méthodes de traitement du cancer | |
| IL281492A (en) | Modulators of pnpla3 expression | |
| EP3355954A4 (fr) | Méthodes et compositions d'administration | |
| EP3368077A4 (fr) | Compositions et méthodes de transduction tumorale | |
| MA48730A (fr) | Compositions et méthodes de traitement de synucléinopathies | |
| IL272851A (en) | Methods of using dipivefrin | |
| PT3277270T (pt) | Composições e métodos de tratamento de anemia | |
| JP2018172409A5 (ja) | １５−ｈｅｐｅを含む組成物および同組成物を使用する方法 | |
| EP3600285A4 (fr) | Compositions topiques et méthodes de traitement | |
| EP3658142A4 (fr) | Compositions et méthodes de traitement de la galactosémie | |
| PL3661510T3 (pl) | Sposoby leczenia zmian zachowania | |
| EP3609500A4 (fr) | Traitement d'adipocytes | |
| EP3707869A4 (fr) | Groupement et utilisation de séquences courtes de signaux | |
| IL313083A (en) | Tralipressin compounds and methods of using them | |
| EP3752631A4 (fr) | Nucléotides marqués par une charge et leurs procédés d'utilisation | |
| EP3727452A4 (fr) | Compositions et méthodes de traitement de la néoplasie |